Skip to main content

Table 1 Univariate analysis of overall survival

From: Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients

Factors No. MST 95% CI p value
Age, y
  > 66 109 21.5 15.3–32.6 0.76
  ≤ 66 128 21.6 14.6–29.1  
Serum SCC antibody
  > 2 ng/mL 65 23.0 10.0–29.0 0.42
  ≤ 2 ng/mL 172 21.6 18.0–30.6  
Combined CTX
 Without 38 10.8 6.3–21.5 0.000055
 With 199 26.0 18.5–32.8  
DFI
  ≤ 12 mo 119 14.5 12.8–18.8 0.0013
  > 12 months 118 30.6 23.2–42.0  
DFI
  ≤ 24 months 183 18.0 14.2–23.2 0.0041
  > 24 months 54 41.0 26.0–116.0  
KPS
  < 90% 83 14.6 12.3–28.0 0.11
  ≥ 90% 154 26.0 18.0–32.8  
No. of LN metastasis
 Mono 165 26.0 17.8–33.0 0.44
 Multiple 72 18.8 14.6–28.5  
LN max diameter
  > 22 mm 109 15.7 13.5–23.5 0.0052
  ≤ 22 mm 128 29.1 19.8–41.1  
LN location
 Distant 90 20.2 14.2–27.0 0.41
 Locoregional 147 26.4 18.0–34.3  
Histopathology
 SCC 231 23.0 18.0–28.5 0.55
 Others 6 15.0 12.0-NA  
  1. Abbreviation: No. number, MST median survival time, CI confidence interval, SCC squamous cell carcinoma, CTX chemotherapy, DFI disease-free interval, KPS Karnofsky performance status, LN lymph node